NOL6

Across TCGA pan-cancer cohorts, NOL6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NOL6 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NOL6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOL6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where NOL6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.599	0.850	<.001	57	view →
LUAD	DFS	Median	III,IV	0.716	0.253	.006	13	view →
GBM	DFS	Median	All	0.442	0.210	.011	12	view →
LSCC	DFS	Quartile	II,III,IV	0.871	0.490	.019	10	view →
PDAC	DFS	Quartile	III,IV	0.448	0.806	.035	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NOL6–CCRCC (DFS)

Open the CCRCC breakdown →